The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
WASHINGTON >> The nation’s three largest pharmacy benefit managers have significantly marked up the prices of certain ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The FTC study examines the practices of PBMs to ensure fair competition and transparency. The FTC found that from 2017 to 2022, the three big PBMs imposed substantial price markups on 51 specialty ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.
As Lina Khan, chair of the Federal Trade Commission, ends her tenure this week the FTC posted a second report in six months ...
CVS said it has complied with the FTC’s demands by providing more than 2 million documents and 7 terabytes of data. A company spokesman said the lawsuit appeared to be linked to CVS’ attempt to have ...